New ETF Book by Larry Connors - Click here to read more
"This honor is being bestowed upon you for the exemplary work that you have done in the field of biochemistry," wrote James W. Davis, chair, 2009 Hall of Fame committee. The award citation from Hunter College reads: "A pioneer in the scientific field of Proteomics... at Baylor College of Medicine, Ira Goldknopf and Harris Busch made the earliest proteomic discovery. Through this work, and that of many others over the years, this system called the Ubiquitin Conjugation System is now known to play a major role in the management of the inventories of proteins in the cell, cell proliferation, programmed cell death and most regulatory functions of health and disease at the cellular level."
Founder and Chief Scientific Officer of Power3 Medical Products, Inc., Dr. Goldknopf and his team discovered the serum proteomic tests for early detection of breast cancer, for early diagnosis of Alzheimer's, Parkinson's, ALS and other tests and drug targets. He has been awarded the NASA Space Act Award for the invention of commercial applications for NASA technology and, while he was not named a laureate, he has been cited for his contributions to the 2004 Nobel Prize in Chemistry. He is the author of more than 70 publications, book chapters and patents.
Helen R. Park, Power3's interim CEO, stated that: "Power3 is excited that Hunter College recognizes the importance of Dr. Goldknopf's contributions to proteomics discovery and the development of diagnostic tests that will benefit the medical community and all of health care."
About Power3 Medical Products, Inc.
Power3 Medical Products (www.power3medical.com) is a leading bio-medical company engaged in the commercialization of diagnostic tests and drug targets for neurodegenerative disease and cancer, employing proteomic biomarkers, pathways, and mechanisms of diseases. Power3's patent-pending technologies are being used to develop diagnostic tests for the early detection, prognosis, response to therapy, as well as targeted therapy and personalized medicine. Power3 expects to complete phase II clinical validation trials of its blood serum diagnostics for Alzheimer's disease and Parkinson's disease (NuroPro(R)) in 2009, which will be followed by a filing with the FDA. Power3 operates a state-of-the-art CLIA certified laboratory in The Woodlands (Houston), Texas. Power3 continues to evolve and enhance its IP portfolio, employing sensitive and specific combinations of biomarkers that it has discovered in a broad range of diseases. Power3 utilizes these biomarkers as the basis of highly selective blood-based tests for Alzheimer's and Parkinson's diseases, ALS, as well as breast cancer.
Safe Harbor Statement:
This press release contains forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in this press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement contained herein. Specific forward looking statements made in this news release include, but are not limited to, the statement that Power3 is ready to begin marketing, and the launch of its NuroPro and BC-SeraPro blood test kits to the health care industry.
Contact: Power3 Medical Products, Inc. Helen Park CEO 281-466-1600 Email Contact or Investor Relations: Equiti-trend Advisors LLC (800) 953-3350 toll-free (858) 436-3350 local or international
SOURCE: Power3 Medical Products, Inc.
http://www2.marketwire.com/mw/emailprcntct?id=D3757B0F432B49FB
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302
© Copyright 2009 The Connors Group, Inc.
